Dyne Therapeutics Inc DYN 深 沪
交易中 07-01 09:52:01 美东时间
22.035
-0.175
-0.79%
华盛通- 最 高22.29
- 今 开22.15
- 成交量 3.15万股
- 最 低 21.95
- 昨 收 22.21
- 总市值 36.43亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 8.245
- 委 比 -97.01%
- 总股本 1.65亿
- 历史最高 47.45
- 量 比 0.73
- 振 幅 1.53%
- 历史最低 4.30
- 每 手 1
- 风险率 3.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating
TD Cowen analyst Joseph Thome initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating.
06-27 00:39
Dyne Therapeutics director Jason P. Rhodes reports $5.15 million common share disposal
Dyne Therapeutics director Jason P. Rhodes reports $5.15 million common share disposal Dyne Therapeutics director Jason P. Rhodes reported sales of 267,760 common shares on June 23-25 under a Rule 10b5-1 plan. Shares sold at weighted-average prices of USD 21.13, USD 21.02, USD 21.1 across the three
06-26 20:41
Dyne Therapeutics expands Hercules Capital debt facility to up to $400 million
Dyne Therapeutics expands Hercules Capital debt facility to up to $400 million Dyne Therapeutics amended its senior secured term loan facility with Hercules Capital, expanding total capacity to up to $400 million. The amendment funded $50 million at closing, lifting total borrowings under the facili
06-17 19:35
Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basivarsen In Individuals With DM1
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused
06-03 19:34
Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1
Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1 Dyne Therapeutics completed enrollment in a 71-participant registrational expansion cohort of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1. Results have not been presented; topline data are schedu
06-03 19:30
Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment -- Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary
05-20 19:49
Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy
Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen for Duchenne muscular dystrophy patients eligible for exon 51 skipping, positioning the study as the confirmatory program for a planned U.S. a
05-20 19:46
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Dyne Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Dyne Therapeutics shares are trading higher after the company reported better-t...
05-11 22:58
